Alterity Therapeutics July 2025 Corporate Presentation

SEC Filing 6-K (0001213900-25-069557)

Alterity Therapeutics, a late clinical-stage biopharmaceutical company, focuses on developing treatments for neurodegenerative diseases. Their lead candidate, ATH434, targets multiple system atrophy (MSA), a Parkinsonian disorder with no approved treatment. ATH434 has shown positive Phase 2 data, demonstrating efficacy on functional endpoints endorsed by the FDA/EMA. The drug has received Fast Track and Orphan Drug Designations for MSA. The company's clinical development program includes a natural history study, open-label trials, and a double-blind placebo-controlled trial. ATH434 aims to address the underlying pathology of neurodegenerative diseases by redistributing excess labile iron in the CNS and reducing α-synuclein aggregation. The presentation highlights the significant commercial opportunity in MSA, with potential U.S. annual peak sales exceeding $1.1 billion.